Increased insulin clearance in peroxisome proliferator-activated receptor γ2 Pro12Ala

被引:26
|
作者
Tschritter, O [1 ]
Fritsche, A [1 ]
Stefan, N [1 ]
Haap, M [1 ]
Thamer, C [1 ]
Bachmann, O [1 ]
Dahl, D [1 ]
Maerker, E [1 ]
Teigeler, A [1 ]
Machicao, F [1 ]
Häring, H [1 ]
Stumvoll, M [1 ]
机构
[1] Univ Tubingen, Med Klin, Abt Endokrinol Stoffwechsel & Pathochem, D-72076 Tubingen, Germany
来源
METABOLISM-CLINICAL AND EXPERIMENTAL | 2003年 / 52卷 / 06期
关键词
D O I
10.1016/S0026-0495(03)00071-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The Pro12Ala polymorphism of the peroxisome proliferator-activated receptor (PPARgamma2) is associated with reduced risk for type 2 diabetes. Although increased insulin sensitivity of glucose disposal and lipolysis has been reported, the exact mechanism by which the risk reduction is conferred is not clear. Because the conclusion of greater insulin sensitivity hinged upon lower insulin levels in some studies, it is possible that more efficient insulin clearance is involved. We therefore estimated insulin clearance during a euglycemic hyperinsulinemic clamp (insulin infusion rate divided by steady-state insulin concentration, 229 normal glucose tolerant [NGT] subjects), an oral glucose tolerance test (OGTT) (mean C-peptide divided by mean insulin concentrations, 406 NGT, 54 impaired glucose tolerant or mildly diabetic subjects), and a hyperglycemic clamp (120 minutes, 10 mmol/L, C-peptide divided by insulin in the steady-state, 56 NGT subjects). In the carriers of the Ala allele (prevalence similar to24%), insulin clearance in all 3 protocols was significantly greater (similar to 10%), than in controls. While the results from the euglycemic clamp reflect both hepatic and peripheral insulin clearance; those from the OGTT and the hyperglycemic clamp reflect mainly hepatic insulin extraction. Free fatty acids (FFA) during the steady state of the euglycemic hyperinsulinemic clamp were significantly lower in carriers of the Ala allele (26 +/- 5 mumol/L) than in controls (46 +/- 3 mumol/L, P = .02). In conclusion, the Pro12Ala polymorphism is associated with increased insulin clearance. This could be the result of reduced FFA delivery, which has been shown to improve hepatic insulin removal and sensitivity. Because PPARgamma2 is mainly expressed in adipose tissue, one of the main regulatory effects of the polymorphism may well be the more efficient suppression of (possibly intra-abdominal) lipolysis. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:778 / 783
页数:6
相关论文
共 50 条
  • [1] The peroxisome proliferator-activated receptor-γ2 pro12Ala polymorphism
    Stumvoll, M
    Häring, H
    DIABETES, 2002, 51 (08) : 2341 - 2347
  • [2] Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-γ2 gene is associated with increased antilipolytic insulin sensitivity
    Stumvoll, M
    Wahl, HG
    Löblein, K
    Becker, R
    Machicao, F
    Jacob, S
    Häring, H
    DIABETES, 2001, 50 (04) : 876 - 881
  • [3] The role of the Pro12Ala polymorphism in peroxisome proliferator-activated receptor γ in diabetes risk
    Toenjes, Anke
    Stumvoll, Michael
    CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, 2007, 10 (04): : 410 - 414
  • [4] Pro12Ala polymorphism of the peroxisome proliferator-activated receptor γ2 in patients with fatty liver diseases
    Rey, Johannes W.
    Noetel, Andrea
    Hardt, Aline
    Canbay, Ali
    Alakus, Hakan
    zur Hausen, Axel
    Dienes, Hans Peter
    Drebber, Uta
    Odenthal, Margarete
    WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (46) : 5830 - 5837
  • [5] Peroxisome proliferator-activated receptor γ polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes
    Pollex, Rebecca L.
    Mamakeesick, Mary
    Zinman, Bernard
    Harris, Stewart B.
    Hegele, Robert A.
    Hanley, Anthony J. G.
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2007, 21 (03) : 166 - 171
  • [6] Pro12Ala polymorphism of the peroxisome proliferator-activated receptor γ2 in patients with fatty liver diseases
    Johannes W Rey
    Andrea Noetel
    Aline Hardt
    Ali Canbay
    Hakan Alakus
    Axel zur Hausen
    Hans Peter Dienes
    Uta Drebber
    Margarete Odenthal
    World Journal of Gastroenterology, 2010, 16 (46) : 5830 - 5837
  • [7] The Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-γ2 is not associated with type 2 diabetes
    Andersen, G
    Ek, J
    Urhammer, SA
    Eiberg, H
    Borch-Johnsen, K
    Hansen, T
    Pedersen, O
    DIABETOLOGIA, 2000, 43 : A87 - A87
  • [8] Pro12Ala substitution in the peroxisome proliferator-activated receptor-γ2 is not associated with type 2 diabetes
    Mancini, FP
    Vaccaro, O
    Sabatino, L
    Tufano, A
    Rivellese, AA
    Riccardi, G
    Colantuoni, V
    DIABETES, 1999, 48 (07) : 1466 - 1468
  • [9] Pro12Ala polymorphism in peroxisome proliferator-activated receptorγ2 (PPARγ2):: beta-cell function and insulin sensitivity
    Fritsche, A
    Madaus, A
    Tschritter, O
    Özeker, M
    Wulle, EL
    Machicao, F
    Häring, H
    Stumvoll, M
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2001, 126 (20) : 580 - 584
  • [10] Contribution of the Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma 2 gene in relation to obesity
    Zahri, Mohd Khairi
    Emilia, Apidi
    Rawi, Rohayu Izanwati Mohd
    Taib, Wan Rohani Wan
    Sani, Aliya Irshad
    Baig, Atif Amin
    META GENE, 2016, 10 : 39 - 44